2024
Chaos and Confusion: Antipsychotic Use in the ICU Within the Veterans Healthcare System During the COVID Pandemic
Murphy I, Akgun K, Burk M, Jiang R, Bryan K, Morneau K, Sutherland A, Rightnour E, Rosen A, Zavala S, Franck A, Davids B, Lee J, Wong M, Providence S, Schmitt T, Exline T, Guilbeault T, Drumright K, Klenosky B, Pisani M, Witcher P. Chaos and Confusion: Antipsychotic Use in the ICU Within the Veterans Healthcare System During the COVID Pandemic. 2024, a2717-a2717. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2717.Peer-Reviewed Original ResearchPlasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteins
2023
Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly interventionReproductive Psychiatry
Forray A, McMahon J. Reproductive Psychiatry. 2023, 479-491. DOI: 10.1016/b978-0-323-95702-1.00040-3.Peer-Reviewed Original ResearchPsychiatric disordersExacerbation of psychiatric symptomsRisks of untreated psychiatric illnessTreating mood symptomsUntreated psychiatric illnessFemale sexTreatment of premenstrual disordersPerinatal periodAntipsychotic useMood symptomsPsychiatric symptomsPsychiatric illnessReproductive-age patientsSymptom stabilityPostpartum depressionPremenstrual disordersMale sexDisordersPregnant individualsSymptomsPerimenopausal symptomsReproductive risksUnique manifestationUnique considerationsBirth
2022
Evaluation of Antipsychotic Reduction Efforts in Patients With Dementia in Veterans Health Administration Nursing Homes
Gerlach LB, Maust DT, Kales HC, Chang M, Kim HM, Wiechers IR, Zivin K. Evaluation of Antipsychotic Reduction Efforts in Patients With Dementia in Veterans Health Administration Nursing Homes. American Journal Of Psychiatry 2022, 179: 544-552. PMID: 35615813, PMCID: PMC9349465, DOI: 10.1176/appi.ajp.21060591.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCNS-active medicationsVHA Nursing HomesNursing homesAnxiolytic prescribingOverall prescribingVeterans Health Administration nursing homesNursing home patientsNursing home residentsInterrupted time series designAntipsychotic reductionQuarterly prevalenceMedication classesOpioid medicationsAntidepressant prescribingAntipsychotic useMedication prescribingHome patientsPsychotropic medicationsLabel useHome residentsSimilar riskMedicationsPrescribingHealth AdministrationAntipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China
Ouyang F, He J, Cheng X, Zhou W, Xiao S, Fang J. Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China. Frontiers In Psychiatry 2022, 13: 754775. PMID: 35280179, PMCID: PMC8909132, DOI: 10.3389/fpsyt.2022.754775.Peer-Reviewed Original ResearchAntipsychotic usePatients’ baseline body mass index.Public Health Service ProgramType 2 diabetes mellitusMental health officersAntipsychotic monotherapyRisk of T2DMSchizophreniaAntipsychoticsProportion of animal productsCumulative person-yearsBaseline fasting plasma glucose levelsHazard ratioClozapineRisperidoneRisk of type 2 diabetes mellitusFasting plasma glucose levelsT2DM riskBaseline body mass indexDiabetes-free patientsPerphenazineHealth service programsDevelopment of type 2 diabetes mellitusChlorpromazineHigher risk of T2DM
2021
Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 2021, 16: e0244944. PMID: 33596211, PMCID: PMC7888647, DOI: 10.1371/journal.pone.0244944.Peer-Reviewed Original ResearchConceptsAntipsychotic-naive patientsBody weight changesBody weight gainWeight gainPsychiatric diagnosisNaive patientsWeight changeAntipsychotic useBodyweight gainAntipsychotic-naive groupMore weight gainDiagnosis of schizophreniaAntipsychotic switchMost antipsychoticsShort followSwitch studyMetabolic disturbancesClinical trialsOutcome measuresAntipsychoticsPatientsBody weightNaive groupSwitch groupDiagnosis
2019
Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia
Boivin Z, Perez M, Atuegwu N, Metersky M, Alvarez C, Anzueto A, Mortensen E. Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia. ERJ Open Research 2019, 5: 00223-2018. PMID: 31720299, PMCID: PMC6826252, DOI: 10.1183/23120541.00223-2018.Peer-Reviewed Original ResearchAtypical antipsychotic useAntipsychotic useAtypical antipsychoticsPatients 65Retrospective cohort studyOdds of mortalityOlder adult patientsAtypical antipsychotic usersAdult patientsCohort studyAntipsychotic usersSafety dataCardiac conditionsPneumoniaPatientsPrimary analysisPsychiatric conditionsAntipsychoticsMortalityNonusersOddsAssociationMedicationsAdmissionConfoundersAntipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis
Kucukgoncu S, Guloksuz S, Celik K, Bahtiyar MO, Luykx JJ, Rutten BPF, Tek C. Antipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis. Schizophrenia Bulletin 2019, 46: 311-318. PMID: 31167033, PMCID: PMC7442324, DOI: 10.1093/schbul/sbz058.Peer-Reviewed Original ResearchConceptsGestational diabetes mellitusAntipsychotic exposureRisk ratioGDM riskHealthy controlsRisk of GDMControl groupSystematic reviewRisk of GestationalModifiable risk factorsConfidence intervalsCumulative risk ratioHealthy control groupSystematic literature searchLifestyle modificationDiabetes mellitusPrimary outcomeGestational ageAntipsychotic usePregnant womenRisk factorsStudy qualityExposure groupMeta-analysisPregnancy monitoring
2018
Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.
Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015. The Journal Of Clinical Psychiatry 2018, 79: 17m11970. PMID: 29469245, PMCID: PMC5932223, DOI: 10.4088/jcp.17m11970.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntipsychotic prescribingAntipsychotic prescriptionsDepressive disorderNational Ambulatory Medical Care SurveyOffice-based outpatient visitsAmbulatory Medical Care SurveyMultivariable logistic regression analysisMore concomitant medicationsNext-step therapyNext-step treatmentsAdults 75 yearsLogistic regression analysisLong-term effectivenessGreater long-term effectivenessConcomitant medicationsClinical factorsAntipsychotic useOutpatient visitsAntipsychotic treatmentOutpatient settingCare SurveyMental health counselingAntipsychotic agentsDiagnosis of cannabis
2016
Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses
Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Therapeutic Advances In Chronic Disease 2016, 7: 229-245. PMID: 27583123, PMCID: PMC4994396, DOI: 10.1177/2040622316658463.Peer-Reviewed Original ResearchUse of antipsychoticsLewy body dementiaSystematic reviewAlzheimer's diseaseAdverse effectsDiscontinuation of antipsychoticsNonpharmacological management strategiesAdverse effect profileEfficacy of antipsychoticsEffect profileAntipsychotic useModest efficacyCochrane CollaborationAntipsychoticsSevere symptomsFollowing keywordsDementiaLiterature searchFinal analysisAdditional studiesOfficial English translationsPatientsDiseaseEnglish-language journalsBibliographic databases
2013
The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical Center
Hermes E, Sernyak M, Rosenheck R. The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical Center. Epidemiology And Psychiatric Sciences 2013, 23: 281-288. PMID: 24007653, PMCID: PMC6998245, DOI: 10.1017/s2045796013000449.Peer-Reviewed Original ResearchPost-traumatic stress disorderMedical CenterUS Veterans Health Administration medical centersVeterans Health Administration medical centersSingle Veterans Affairs medical centerVeterans Affairs Medical CenterStress disorderSecond-generation antipsychoticsGoals of sedationSleep/sedationGeneration antipsychoticsAntipsychotic useParticular medicationSole diagnosisClinical correlatesSGA useProvider surveyCommon reasonPsychiatric disordersClinicians' usePsychiatric diagnosisSGALimited evidenceChi-squareDisordersPsychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011
Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research 2013, 148: 99-104. PMID: 23787224, PMCID: PMC3867209, DOI: 10.1016/j.schres.2013.05.019.Peer-Reviewed Original ResearchConceptsMedication use ratesCohort 2High riskCohort 1Alternative treatmentAntipsychotic prescription ratesBaseline antipsychotic useHigh-risk patientsEfficacy of antipsychoticsRate of prescriptionPsychotropic medication useChlorpromazine equivalent doseDuration of treatmentUse ratesNonpsychotic conditionsAntipsychotic dosesMedian ageMedication usePrescription ratesAntipsychotic prescriptionsAntipsychotic useAntipsychotic treatmentPsychotropic medicationsHigh-risk youthPsychiatric disorders
2010
Follow-up of subjects with suspected pre-psychotic state in Taiwan
Liu C, Lai M, Liu C, Chiu Y, Hsieh M, Hwang T, Chien Y, Chen W, Hua M, Hsiung P, Huang Y, Hwu H. Follow-up of subjects with suspected pre-psychotic state in Taiwan. Schizophrenia Research 2010, 126: 65-70. PMID: 21112187, DOI: 10.1016/j.schres.2010.10.028.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisPre-psychotic stateUHR subjectsRate of conversion to psychosisUltra-high-risk groupConversion to psychosisPsychosis risk syndromeFollow-upRisk groupsIntermediate-risk groupNegative symptomsSchizophreniform disorderSchizoaffective disorderPsychotic disordersAntipsychotic useBipolar disorderClinical InterviewFollow-up of subjectsOutcomes of subjectsCommunity-based populationRisk syndromeDiagnostic categoriesPsychosisClinical attentionUHR
2009
Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System
Leslie DL, Mohamed S, Rosenheck RA. Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System. Psychiatric Services 2009, 60: 1175-1181. PMID: 19723731, DOI: 10.1176/ps.2009.60.9.1175.Peer-Reviewed Original ResearchConceptsAntipsychotic medicationLabel useLogistic regression modelsBipolar disorderVeterans Affairs Health Care SystemVeterans AffairsMultivariate logistic regression modelVA administrative databasesHalf of patientsFirst-generation antipsychoticsOff-label useSevere side effectsMental illness diagnosisPosttraumatic stress disorderHealth care systemClinical characteristicsRegression modelsAntipsychotic useVA patientsAdministrative databasesMinor depressionMajor depressionHigher oddsMedicationsSide effects
2008
Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans
Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans. Psychiatric Services 2008, 59: 1184-1190. PMID: 18832505, DOI: 10.1176/ps.2008.59.10.1184.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychotropic medicationsMedication classesStress disorderTreatment of PTSDMental health care usersSymptom-specific responsesComorbid psychiatric disordersUse of anxiolyticsMultivariate logistic regressionDiagnosis of PTSDMajor depressive disorderMental health servicesHealth care usersMedication usePharmacologic treatmentAntidepressant useHealth insurance plansMarketScan databaseAntipsychotic usePrivate health insurance plansPharmacological treatmentDepressive disorderSpecific symptomsMillions of AmericansPharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection.
Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. The Journal Of Clinical Psychiatry 2008, 69: 959-65. PMID: 18588361, DOI: 10.4088/jcp.v69n0611.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Anxiety AgentsAntipsychotic AgentsAnxietyComorbidityDrug TherapyFemaleHumansHypnotics and SedativesInternational Classification of DiseasesMaleMiddle AgedPsychotropic DrugsSleep Initiation and Maintenance DisordersStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsConceptsPosttraumatic stress disorderAnxiolytic/Psychotropic medicationsVeterans AffairsMedication classesService usePharmacotherapy of PTSDMental health service useTreatment of PTSDGreater mental health service usePsychotropic medication classesSedative-hypnotic useHealth service useMultivariable logistic regressionAntidepressant useMedication usePsychotropic prescriptionsAntipsychotic useSuch medicationsVA patientsPsychotropic pharmacotherapySymptom responseDepressive disorderVeteran characteristicsSpecific symptoms
2002
Triglyceride, cholesterol and weight changes among risperidone-treated youths
Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. European Child & Adolescent Psychiatry 2002, 11: 129-133. PMID: 12369772, DOI: 10.1007/s00787-002-0255-5.Peer-Reviewed Original ResearchConceptsRisperidone-treated youthsMean ageWeight gainRetrospective chart reviewWeight changeRegular laboratory monitoringAtypical antipsychotic useSignificant weight gainSample mean ageChart reviewRisperidone doseAntipsychotic useSerum triglyceridesLaboratory monitoringTriglyceride levelsCholesterol levelsLipid dysregulationAdolescent inpatientsTriglyceridesPreliminary reportMeasures analysisSuch associationsCholesterolSignificant changesAverage length
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply